Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Change in Accured Expenses: 2019-2025

Historic Change in Accured Expenses for Harmony Biosciences Holdings (HRMY) over the last 6 years, with Sep 2025 value amounting to $28.0 million.

  • Harmony Biosciences Holdings' Change in Accured Expenses rose 15.24% to $28.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.1 million, marking a year-over-year decrease of 6.25%. This contributed to the annual value of $11.8 million for FY2024, which is 74.61% down from last year.
  • Latest data reveals that Harmony Biosciences Holdings reported Change in Accured Expenses of $28.0 million as of Q3 2025, which was up 498.83% from -$7.0 million recorded in Q2 2025.
  • In the past 5 years, Harmony Biosciences Holdings' Change in Accured Expenses ranged from a high of $37.8 million in Q3 2022 and a low of -$22.8 million during Q4 2022.
  • For the 3-year period, Harmony Biosciences Holdings' Change in Accured Expenses averaged around $6.7 million, with its median value being $3.1 million (2023).
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first soared by 535.86% in 2022, then crashed by 637.48% in 2024.
  • Over the past 5 years, Harmony Biosciences Holdings' Change in Accured Expenses (Quarterly) stood at $8.7 million in 2021, then tumbled by 360.98% to -$22.8 million in 2022, then surged by 235.23% to $30.8 million in 2023, then crashed by 59.13% to $12.6 million in 2024, then increased by 15.24% to $28.0 million in 2025.
  • Its last three reported values are $28.0 million in Q3 2025, -$7.0 million for Q2 2025, and -$5.5 million during Q1 2025.